Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer-Reference-Cited by-同舟云学术

Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer

Published:2017-02-01 Issue:2 Volume:3 Page:202
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Liu Rengyun¹,Bishop Justin²,Zhu Guangwu¹,Zhang Tao¹,Ladenson Paul W.¹,Xing Mingzhao¹

Affiliation:

1. Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report;Oral Oncology;2024-11

2. Molecular insights into the role of mixed lineage kinase 3 in cancer hallmarks;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Association of BRAF or TERT Promoter Mutations and Advanced Papillary Thyroid Carcinoma;Anticancer Research;2024-06-26

4. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro;International Journal of Molecular Sciences;2024-06-19

5. A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma;Endocrine;2024-06-17